Management at South African pharmaceutical multinational Aspen Pharmacare appeared confident when announcing their full year results for 2023, celebrating a record H2 following a shaky start to the year, even as the market expressed reservations about the firm’s performance going into FY2024.
Key Takeaways:
-
A weak H1 gave way to a much stronger H2 for Aspen in FY 2023, and managing director Stephen Saad appears confident in the firm's performance and prospects
EBITDA ultimately aligned with the prior year’s performance at ZAR11bn ($572.9m), following a weak H1 where it was down 11%...






